Fed Minutes Preview: What Wednesday's Release Could Mean for 2026 Rate Cuts
The Federal Reserve releases December meeting minutes on Wednesday. With seven officials wanting no 2026 cuts, the notes could reveal how divided policymakers really are.
TRENDING TOPICS
760 articles found for "passive income"
The Federal Reserve releases December meeting minutes on Wednesday. With seven officials wanting no 2026 cuts, the notes could reveal how divided policymakers really are.
Wall Street strategists predict the S&P 500 could reach 7,500-8,000 by end of 2026, representing 8-15% upside. Key drivers include AI earnings and moderate Fed easing.
Gold futures reached $4,579.60 per ounce on December 27, marking the 54th record close of 2025. The precious metal is up 70% year-to-date, its best performance since 1979.
With days left in 2025, review the year's biggest winners (gold, Nvidia, small caps) and losers (Nike, Oracle) to position your portfolio for 2026.
Gold futures hit $4,469 per ounce, up nearly 70% for 2025. Geopolitical tensions, Fed rate cuts, and dollar weakness are driving the historic rally.
The U.S. economy expanded at a 4.3% annualized rate in Q3 2025, far exceeding expectations and complicating the Fed's rate-cut calculus for 2026.
Vanguard reverses its longtime crypto ban, opening Bitcoin and Ethereum ETF access to its 50 million brokerage customers. The move signals mainstream adoption.
Cleveland Fed President Beth Hammack signals the Fed may hold rates steady for months ahead. Markets now pricing 75% chance of no January move.
FedEx reports Q2 earnings beat with 19% EPS growth as freight spinoff preparations advance. Stock rises on raised guidance despite MD-11 fleet headwinds.
Micron stock jumped 12% after posting record earnings and guiding for $18.7 billion in Q2 revenue. The AI memory boom shows no signs of slowing.
Morgan Stanley upgraded Hershey to overweight with a $211 price target as cocoa cost pressures ease. Here's why the chocolate maker may be turning a corner.
Pfizer's 2026 outlook falls short of Wall Street estimates as COVID-19 product sales decline by $1.5 billion. Here's what the guidance means for pharma investors.